Article · Volume 12, Issue 1 · pp. 144–150

Prospective Role of Unani Pharmacopeial Formulation Safoof Hijrul Yahood in Preventing Recurrence of Nephrolithiasis: An Open Labeled Clinical Study

Arjumand Shah¹, Huma H¹, Arsheed Iqbal¹, Umar Jahangir³, Kausar Shah¹, Sabia S¹, Arif H Hanga¹, Shaista Urooj², TA Rafiqi¹

¹Research Officer, Regional Research Institute of Unani Medicine, Srinagar, Jammu and Kashmir, INDIA.
²Regional Research Institute of Unani Medicine, New Delhi, INDIA.
³School of Unani Medical Education and Research, Jamia Hamdard, New Delhi, INDIA.

Abstract

Background: The recurrence of nephrolithiasis has high incidence in northern region of India posing major health problems.Aim and Objectives: To study the efficacy of Unani pharmacopeial formulationSafoof Hajrul Yahood (SHY) in preventing recurrence of nephrolithiasis.Study Design:Open labeled, single arm, clinical trial.Materials and Methods:The study was conducted on 75 cases of uncomplicated nephrolithiasis (Hisat al Kuliya). The post-trial assessment was done on 49 cases after five years. Subsequent to written and informed consent, patients of All genders between 18-60 years with 6-8mm calculi were given SHY (5g twice daily orally for 8 weeks). Patients were followed up fortnightly, investigated at day 0, 15 and 60 and enquired about their diet and fluid intake. The data was analyzed on Tukey-Kramer multiple comparison test and pairedttest.Results:Mean age of patients was 33.45±10.99 years CI (30.92-35.99). SHY reduced 24 hr calcium excretion highly significantly (p<0.0001). Calculus clearance rate was 64% and recurrence after five years was 29.16%. The drug was well tolerated.Conclusion:SHY probably corrects crystalloid colloidal imbalance or the oxalate metabolism and/or renal functions; thus, preventing recurrence. However, the exact mechanism of the drug needs to be studied.

Keywords: Crystalloid colloidal imbalance; Nephrolithiasis; Oxalate metabolism; Recurrence Unani

The full text of this article is available as a PDF. Open the PDF.